Actavis Launches Losartan In Switzerland

Actavis has launched the antihypertensive drug ‘Losartan’ on day one, as the patent expired in Switzerland. The product was launched by the company under its own name, and by customers of Medis, Actavis’ third-party sales division.

Losartan, marketed by Merck under the brand name Cozaar, is mainly used to treat high blood pressure. Generic Losartan by Actavis is available in Switzerland in 50mg and 100mg tablets.

Losartan Actavis was developed and produced by Actavis in Iceland. The product was launched on 21 December, when the patent expired in Switzerland.

Losartan is an angiotensin II receptor antagonist drug used mainly to treat high blood pressure (hypertension). Losartan may also delay progression of diabetic nephropathy and is also indicated for the reduction of renal disease progression in patients with type 2 diabetes, hypertension and microalbuminuria (>30mg/24 hours) or proteinuria (>900mg/24 hours).

Losartan is available in a combination formulation with a low dose thiazide diuretic to achieve an additive antihypertensive effect.